Bortezomib vs Ixazomib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Proteasome · full Multiple Myeloma pipeline

Bortezomib

Marketed by Takeda Pharmaceutical Company and partners

Approved in Multiple Myelomasmall molecule (proteasome inhibitor)
Partial signal

NCT00048230 · Phase 3 · completed

APEX randomized 620 patients with relapsed multiple myeloma to bortezomib or high-dose dexamethasone in an open-label design. Its primary endpoint, time to progression, is a clinical outcome and was met. An open-label trial is never graded strong under the rubric, so the grade is moderate.

Next expected readout: November 2026 · NCT06505369 (registry estimate)

Reported efficacy

Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73 (met)

Result source: NCT00722566

Ixazomib

Marketed by Takeda Pharmaceutical Company and partners

Approved in Multiple Myelomasmall molecule
Reliable signal

NCT01564537 · Phase 3 · completed

Participants were randomly assigned and quadruple-blinded to ixazomib plus lenalidomide and dexamethasone or matching placebo plus lenalidomide and dexamethasone, with 360 and 362 participants, respectively. The hard clinical primary endpoint of independently assessed progression-free survival was met: median progression-free survival was 20.6 versus 14.7 months, with a statistically significant difference between groups (p=0.012).

Next expected readout: March 2027 · NCT04068597 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47) (met)

Result source: NCT02312258

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBortezomibIxazomib
PFS, median11.2 vs 7.1vs BTZ+LD-DEXn 281NCT01734928
14 other results
20.6 vs 14.7+5.9 vs placebon 360NCT01564537
13 other results
OS, median83.0 vs 53.6vs Velcade, Melphalan and Prednisonen 350NCT02195479
10 other results
53.6 vs 51.6+2 vs placebon 360NCT01564537
6 other results
ORR90.9% vs 73.9%vs Velcade, Melphalan and Prednisonen 350NCT02195479
12 other results
78.3% vs 71.5%+6.8 vs placebon 360NCT01564537
10 other results
VGPR or better71.1% vs 49.7%vs Velcade, Melphalan and Prednisonen 350NCT02195479
8 other results
48.1% vs 39%+9.1 vs placebon 360NCT01564537
2 other results
  • 50% 4 mg + 25 mg + 40 mg · n 32 · Phase 2 · primary NCT02917941
  • 42.2% vs 43.6% n 45 · Phase 4 · secondary NCT03416374
MRD negativity53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
5 other results
59% vs 50%+9 vs placebowk 72 · n 335NCT01850524
3 other results

PFS, median

Bortezomib
11.2 vs 7.1vs BTZ+LD-DEXn 281NCT01734928
14 other results
Ixazomib
20.6 vs 14.7+5.9 vs placebon 360NCT01564537
13 other results

OS, median

Bortezomib
83.0 vs 53.6vs Velcade, Melphalan and Prednisonen 350NCT02195479
10 other results
Ixazomib
53.6 vs 51.6+2 vs placebon 360NCT01564537
6 other results

ORR

Bortezomib
90.9% vs 73.9%vs Velcade, Melphalan and Prednisonen 350NCT02195479
12 other results
Ixazomib
78.3% vs 71.5%+6.8 vs placebon 360NCT01564537
10 other results

VGPR or better

Bortezomib
71.1% vs 49.7%vs Velcade, Melphalan and Prednisonen 350NCT02195479
8 other results
Ixazomib
48.1% vs 39%+9.1 vs placebon 360NCT01564537
2 other results
  • 50% 4 mg + 25 mg + 40 mg · n 32 · Phase 2 · primary NCT02917941
  • 42.2% vs 43.6% n 45 · Phase 4 · secondary NCT03416374

MRD negativity

Bortezomib
53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
5 other results
Ixazomib
59% vs 50%+9 vs placebowk 72 · n 335NCT01850524
3 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
19 other shared endpoints and safety

Coverage. Bortezomib: 23 of 23 rows · Ixazomib: 23 of 23 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBortezomib
Rows use multiple source trials
Ixazomib
Rows use multiple source trials
Complete
responder rate · % of participants
53.1% (n=98) vs 51% (n=96) Thalidomide + Prednisolone @ 52wka,b
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
10.7% (n=131) vs 7.3% (n=137) placebo
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
26% (n=351) vs 14% (n=354) placeboa,b
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
Duration of Response
time to event · months
NA vs 21.3 Velcade, Melphalan and Prednisone monthsa,b
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
3 other source trials
13.7 vs 10.94 BTZ+LD-DEX months
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
17.28 vs 12.88 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
NA vs NA Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
26 vs 21.7 placebo monthsa,b
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
3 other source trials
50.6 vs 37.5 placebo months
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
28.03 vs 15.31 Bortezomib + Lenalidomide + Dexamethasone months
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
14.8 vs 14.3 Pomalidomide months4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
Duration of Response
time to event · months
No placebo or comparator arm
18.3 monthsc,d,a,b
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
19.8 months
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
22.4 months
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
22.92 months*c,d,a,b
NCT02389517 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1.91 years as posted
show 1 more dose
23.76 months*
NCT02389517 · Phase 2 · registry result, not featured evidence · converted to months from 1.98 years as posted
EORTC QLQ-C30 GHS
absolute change · score
9.8 vs 8.9 Velcade, Melphalan and Prednisone score @ 208wka,e,b
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
-4.1 vs -1.7 placebo scorea,e,b
NCT02181413 · Phase 3
MRD Negative
responder rate · % of participants
No placebo or comparator arm
25.4% (n=67)c,a,b
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
21.5% (n=65)
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
18% (n=11) @ 52wkc,a,b
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
31% (n=13) @ 52wk
NCT02389517 · Phase 2 · registry result, not featured evidence
ORR
event count · % of participants
No placebo or comparator arm
42.5% (n=73)*c,d,a,e,b
NCT00722566 · Phase 3 · converted to % from 31 Participants as posted
show 1 more dose
42.1% (n=145)*
NCT00722566 · Phase 3 · converted to % from 61 Participants as posted
100% (n=12) @ 104wk*d,a,e,b
NCT02412228 · Phase 2 · registry result, not featured evidence · combination · converted to % from 12 Participants as posted
ORR
responder rate · % of participants
No placebo or comparator arm
19% (n=63)d,a,b
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
7 other source trials
73% (n=147)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
70% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
80% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
88.1% (n=67)
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
97% (n=67)
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
90.8% (n=65)
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
80.6% (n=31) @ 24wk
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
73% (n=27) @ 52wkc,d,a,b
NCT02765854 · Phase 2 · registry result, not featured evidence
show 2 more doses
35% (n=22) @ 52wk
NCT02765854 · Phase 2 · registry result, not featured evidence
35% (n=21) @ 52wk
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
Overall Survival
responder rate · % of participants
83.7% (n=257) vs 85.4% (n=254) RVD @ 165wkd,f,e,g
NCT01109004 · Phase 3 · registry result, not featured evidence
94.7% (n=21) vs 86.4% (n=22) placebo @ 91wkd,f,e,g
NCT02440464 · Phase 2 · registry result, not featured evidence
Overall Survival
time to event · months
No placebo or comparator arm
33 monthsc,a,b
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
30.8 months
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
NA monthsa,b
NCT03748953 · Phase 3 · registry result, not featured evidence
9 other source trials
NA months
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT02389517 · Phase 2 · registry result, not featured evidence
NA months4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
23.2 months90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
PFS
responder rate · % of participants
53.9% (n=257) vs 57.8% (n=254) RVD @ 165wkd,f,e,g
NCT01109004 · Phase 3 · registry result, not featured evidence
55.3% (n=21) vs 59.1% (n=22) placebo @ 91wkd,f,e,g
NCT02440464 · Phase 2 · registry result, not featured evidence
PFS
time to event · months
No placebo or comparator arm
52.8 monthsc,a,e,b
NCT02541383 · Phase 3 · registry result, not featured evidence
show 1 more dose
46.7 months
NCT02541383 · Phase 3 · registry result, not featured evidence
21.3 monthsa,e,b
NCT03748953 · Phase 3 · registry result, not featured evidence
7 other source trials
NA months
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT02389517 · Phase 2 · registry result, not featured evidence
22.05 months4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
23.5 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
14.2 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
23 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
5.2 months90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
PFS2
time to event · months
66.73 vs 42.41 Velcade, Melphalan and Prednisone monthsa,e,b
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
84 vs 80.4 placebo monthsa,e,b
NCT02181413 · Phase 3
1 other source trial
51.3 vs 50.3 placebo months
NCT02312258 · Phase 3
Progressive Disease
responder rate · % of participants
45.6% (n=257) vs 41% (n=254) RVD @ 165wkd,f,e,g
NCT01109004 · Phase 3 · registry result, not featured evidence
44.7% (n=21) vs 36.4% (n=22) placebo @ 91wkd,f,e,g
NCT02440464 · Phase 2 · registry result, not featured evidence
Time to Next Treatment
time to event · months
66.8 vs 25.9 Velcade, Melphalan and Prednisone monthsa,e,b
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
16.13 vs 10.84 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
33.1 vs 27.6 placebo monthsa,e,b
NCT02181413 · Phase 3
1 other source trial
22.1 vs 16.1 placebo months
NCT02312258 · Phase 3
Time to Progression
time to event · months
NA vs 19.35 Velcade, Melphalan and Prednisone monthsa,b
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
3 other source trials
NA vs 7.29 Bortezomib + Dexamethasone months
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
9.9 vs 12.6 Bortezomib + Dexamethasone months
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
22.4 vs 17.6 placebo monthsa,b
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
4 other source trials
45.8 vs 26.8 placebo months
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
26.6 vs 21.4 placebo months
NCT02181413 · Phase 3
17.8 vs 9.6 placebo months
NCT02312258 · Phase 3
8.4 vs 5.1 Pomalidomide months4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
Time to Progression
time to event · months
No placebo or comparator arm
9.3 monthsc,a,b
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
6.5 months
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
21.3 monthsa,b
NCT03748953 · Phase 3 · registry result, not featured evidence
4 other source trials
22.57 months4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
30.9 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
16.8 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
32.2 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
Time to Response
time to event · months
0.79 vs 0.82 Velcade, Melphalan and Prednisone monthsa,b
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
2 other source trials
1.41 vs 1.61 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0.8 vs 0.8 Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
1.02 vs 1.87 placebo monthsa,b
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
1 other source trial
2 vs 1.1 Pomalidomide months4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
Time to Response
time to event · months
No placebo or comparator arm
1.4 monthsa,b
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
2.1 monthsa,b
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
VGPR or Better
responder rate · % of participants
No placebo or comparator arm
37% (n=147)c,d,a,b
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
41% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
51% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
50% (n=32)4 mg + 25 mg + 40 mgd,a,b
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
47.3%VELCADE Intravenoush
NCT00722566 · Phase 3
show 32 more results
45.3%VELCADE Subcutaneous
NCT00722566 · Phase 3
n/a: no completion milestone
NCT03652064 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
1.1%Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneSVd Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
15%Arm A: VELCADE, CYCLOPHOSPHAMIDE,
NCT01146834 · Phase 3 · registry result, not featured evidence
0%Arm B: VELCADE & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01109004 · Phase 3 · registry result, not featured evidence
20.7%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneDoxil/Caelyx Plus Velcade (Bortezo
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneVelcade (Bortezomib) Monotherapy
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
70.2%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
68.3%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
74.9%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
68.1%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
64.3%
NCT01801436 · Phase 3 · registry result, not featured evidence
71.6%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
1.5%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
78.5%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
15.4%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02703779 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePart 1 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 2 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
87.1%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
28.1%i
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 40 more results
49.3%Ixazomib + LenDex
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3
18.5%
NCT02181413 · Phase 3
n/a: no completion milestone
NCT02312258 · Phase 3
—
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
0%
NCT03748953 · Phase 3 · registry result, not featured evidence
—
NCT02619682 · Phase 2 · registry result, not featured evidence
3%Arm A (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
2.8%Arm B (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
0%Arm C (Higher-dose Ixazomib Citrat
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
10.8%Arm D (Ixazomib Citrate, Dexametha
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
0%Arm E (Ixazomib Citrate, Cyclophos
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneIxazomib Combination Therapy
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneIxazomib Monotherapy
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
30%Arm I (Ixazomib Citrate, Lenalidom
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
22.7%Arm II (Lenalidomide)
NCT02389517 · Phase 2 · registry result, not featured evidence
0%
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
0%Arm A (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
0%Arm B (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
0%Arm C (Ixazomib, Dexamethasone, Le
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
14.3%
NCT02440464 · Phase 2 · registry result, not featured evidence
70.6%4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
33.3%4 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
66.7%3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
66.7%2.3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
88.9%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
89.7%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
82.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
95%
NCT02499081 · Phase 2 · registry result, not featured evidence
0%4 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
0%3 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
0%90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
25%80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
25%70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—VELCADE Intravenoush
NCT00722566 · Phase 3
show 32 more results
—VELCADE Subcutaneous
NCT00722566 · Phase 3
—
NCT03652064 · Phase 3 · registry result, not featured evidence
—
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
—
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
—Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
0.5%SVd Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Arm A: VELCADE, CYCLOPHOSPHAMIDE,
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm B: VELCADE & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
—
NCT01109004 · Phase 3 · registry result, not featured evidence
5.5%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Doxil/Caelyx Plus Velcade (Bortezo
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
—Velcade (Bortezomib) Monotherapy
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
34.5%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
38.9%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
40.1%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
31.9%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
14.3%
NCT01801436 · Phase 3 · registry result, not featured evidence
—D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
—
NCT02703779 · Phase 2 · registry result, not featured evidence
33.3%Part 1 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
19%Part 2 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
64.5%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
—i
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 40 more results
—Ixazomib + LenDex
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT02181413 · Phase 3
—
NCT02312258 · Phase 3
—
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
—
NCT03748953 · Phase 3 · registry result, not featured evidence
—
NCT02619682 · Phase 2 · registry result, not featured evidence
—Arm A (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm B (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm C (Higher-dose Ixazomib Citrat
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm D (Ixazomib Citrate, Dexametha
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm E (Ixazomib Citrate, Cyclophos
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
0%Ixazomib Combination Therapy
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
13%Ixazomib Monotherapy
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
15%Arm I (Ixazomib Citrate, Lenalidom
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
4.5%Arm II (Lenalidomide)
NCT02389517 · Phase 2 · registry result, not featured evidence
—
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
—Arm A (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
—Arm B (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
—Arm C (Ixazomib, Dexamethasone, Le
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
—4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
—
NCT02440464 · Phase 2 · registry result, not featured evidence
32.4%4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
—4 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
—3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
—2.3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
22.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
21.8%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
29.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
—
NCT02499081 · Phase 2 · registry result, not featured evidence
—4 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
—3 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
35.1%VELCADE Intravenoush
NCT00722566 · Phase 3
show 32 more results
36.1%VELCADE Subcutaneous
NCT00722566 · Phase 3
72.1%
NCT03652064 · Phase 3 · registry result, not featured evidence
53.8%
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
55.1%
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
49.3%DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
18.8%DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
27.5%VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
63.7%Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
—Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
55.9%SVd Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
42.4%SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0%Arm A: VELCADE, CYCLOPHOSPHAMIDE,
NCT01146834 · Phase 3 · registry result, not featured evidence
0%Arm B: VELCADE & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
20.6%
NCT01109004 · Phase 3 · registry result, not featured evidence
34.6%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
27.2%Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
37.7%Doxil/Caelyx Plus Velcade (Bortezo
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
33%Velcade (Bortezomib) Monotherapy
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
53.3%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
50.9%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
58.2%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
29.8%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
100%
NCT01801436 · Phase 3 · registry result, not featured evidence
44.8%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
28.4%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
56.9%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
46.5%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
48%
NCT02703779 · Phase 2 · registry result, not featured evidence
47.6%Part 1 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
33.1%Part 2 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
45.2%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
56.8%i
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 40 more results
—Ixazomib + LenDex
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
65.4%Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
73%Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3
27.4%
NCT02181413 · Phase 3
23.7%
NCT02312258 · Phase 3
37.8%
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
31.4%
NCT03748953 · Phase 3 · registry result, not featured evidence
13.3%
NCT02619682 · Phase 2 · registry result, not featured evidence
48.5%Arm A (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
31.4%Arm B (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
31.4%Arm C (Higher-dose Ixazomib Citrat
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
38.9%Arm D (Ixazomib Citrate, Dexametha
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
58.3%Arm E (Ixazomib Citrate, Cyclophos
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
44.4%Ixazomib Combination Therapy
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
52.2%Ixazomib Monotherapy
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
25%Arm I (Ixazomib Citrate, Lenalidom
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
9.1%Arm II (Lenalidomide)
NCT02389517 · Phase 2 · registry result, not featured evidence
8.3%
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
74.1%Arm A (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
45.5%Arm B (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
47.6%Arm C (Ixazomib, Dexamethasone, Le
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
55.6%4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
52.4%
NCT02440464 · Phase 2 · registry result, not featured evidence
35.3%4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
66.7%4 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
66.7%3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
0%2.3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
47.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
38.5%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
58.8%Ixazomib 4.0 mg + CYC 400 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
40%
NCT02499081 · Phase 2 · registry result, not featured evidence
44%4 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
57.1%3 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
0%90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
42.1%80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
66.7%70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
h
leukopenia 21.6%
fatigue 20.3%
constipation 14.9%
NCT00722566 · Phase 3
show 29 more results
leukopenia 19.7%
weight decreased 15%
constipation 14.3%
NCT00722566 · Phase 3
diarrhoea 56.3%
peripheral sensory neuropathy 55.8%
neutropenia 54.8%
NCT03652064 · Phase 3 · registry result, not featured evidence
neutropenia 50.3%
thrombocytopenia 49.7%
anaemia 31.8%
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
thrombocytopenia 59.7%
peripheral sensory neuropathy 50.2%
diarrhoea 36.2%
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
peripheral sensory neuropathy 60.6%
constipation 50.6%
asthenia 32.8%
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
bronchitis 40.6%
cough 17%
nasopharyngitis 17%
NCT02541383 · Phase 3 · registry result, not featured evidence
bronchitis 36.5%
cough 19.4%
nasopharyngitis 17.5%
NCT02541383 · Phase 3 · registry result, not featured evidence
neutropenia 54%
peripheral sensory neuropathy 48.2%
thrombocytopenia 39.6%
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
thrombocytopenia 61.5%
nausea 50.3%
fatigue 42.1%
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
thrombocytopenia 50%
anaemia 45.5%
nausea 39.4%
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
anemia 40%
nausea 35%
platelet count decreased 35%
NCT01146834 · Phase 3 · registry result, not featured evidence
platelet count decreased 100%
anemia 50%
generalized muscle weakness 50%
NCT01146834 · Phase 3 · registry result, not featured evidence
constipation 35.8%
nausea 32.3%
peripheral sensory neuropathy 24.4%
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 37.9%
peripheral sensory neuropathy 36.9%
neuropathy peripheral 29.1%
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
nausea 47.8%
diarrhoea 44.7%
fatigue 36.2%
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
nausea 39.3%
diarrhoea 38.4%
constipation 30.8%
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
insomnia 5.5%
weight decreased 2.4%
blood sodium decreased 1.8%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
leukopenia 7.4%
platelet count decreased 4.3%
insomnia 3.7%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
hyperuricaemia 5.1%
insomnia 3.8%
cough 3.2%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
fatigue 38.3%
thrombocytopenia 38.3%
diarrhoea 36.2%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 78.6%
white blood cell count decreased 78.6%
platelet count decreased 71.4%
NCT01801436 · Phase 3 · registry result, not featured evidence
thrombocytopenia 56.7%
anaemia 44.8%
constipation 44.8%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
peripheral sensory neuropathy 41.8%
constipation 38.8%
neutropenia 37.3%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
neutropenia 67.7%
diarrhoea 49.2%
anaemia 40%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
fatigue 71.7%
upper respiratory tract infection 67.7%
diarrhoea 65.7%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
diarrhea 58% (placebo 56.9%)
nausea 58% (placebo 64.7%)
anorexia 54% (placebo 51%)
NCT02703779 · Phase 2 · registry result, not featured evidence
neutropenia 81% (placebo 38.1%)
diarrhoea 61.9% (placebo 36%)
thrombocytopenia 61.9% (placebo 46.8%)
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
neutropenia 60.6% (placebo 38.1%)
thrombocytopenia 58.5% (placebo 46.8%)
peripheral sensory neuropathy 51.4% (placebo 52.5%)
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 80.6%
decreased appetite 58.1%
thrombocytopenia 54.8%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
i
diarrhoea 51.5% (placebo 42.6%)
constipation 34.6% (placebo 27.6%)
anaemia 34.1% (placebo 29.2%)
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 32 more results
diarrhoea 77% (placebo 30%)
oedema peripheral 55.5% (placebo 32.5%)
constipation 48.2% (placebo 38.1%)
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
diarrhoea 41.7% (placebo 30%)
oedema peripheral 40.5% (placebo 32.5%)
constipation 36.2% (placebo 38.1%)
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
nausea 39.1% (placebo 15.4%)
diarrhoea 34.3% (placebo 23.6%)
arthralgia 26.6% (placebo 16.6%)
NCT02181413 · Phase 3
nausea 27.9% (placebo 8.3%)
diarrhoea 23.9% (placebo 12.7%)
vomiting 23.9% (placebo 4%)
NCT02312258 · Phase 3
diarrhoea 28.9%
white blood cell count decreased 24.4%
platelet count decreased 20%
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 40% (placebo 25%)
diarrhoea 34.3% (placebo 25%)
vomiting 25.7% (placebo 0%)
NCT03748953 · Phase 3 · registry result, not featured evidence
lymphocyte decreased 36.7%
lymphocyte decreased 33.3%
wbc decreased 33.3%
NCT02619682 · Phase 2 · registry result, not featured evidence
fatigue 87.9%
nausea 84.8%
platelet count decreased 81.8%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
fatigue 94.3%
peripheral sensory neuropathy 88.6%
platelet count decreased 74.3%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
fatigue 82.9%
platelet count decreased 80%
peripheral sensory neuropathy 77.1%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
fatigue 94.4%
diarrhea 80.6%
nausea 77.8%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
anemia 91.7%
fatigue 91.7%
lymphocyte count decreased 91.7%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
anaemia 33.3%
upper respiratory tract infection 33.3%
aspartate aminotransferase increased 22.2%
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
hypertension 17.4%
upper respiratory tract infection 13%
ankle fracture 8.7%
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
diarrhea 95%
fatigue 50%
nausea 50%
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
diarrhea 50%
fatigue 40.9%
upper respiratory infection 27.3%
NCT02389517 · Phase 2 · registry result, not featured evidence
platelet count decreased 91.7%
lymphocyte count decreased 83.3%
rash 83.3%
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
pneumonia 33.3%
colitis 22.2%
upper respiratory infection 22.2%
NCT02765854 · Phase 2 · registry result, not featured evidence
conjunctivits 36.4%
bone pain 18.2%
pneumonia 18.2%
NCT02765854 · Phase 2 · registry result, not featured evidence
thrombocytopenia 42.9%
neutropenia 19%
pneumonia 19%
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
4 mg
diarrhoea 38.9%
peripheral sensory neuropathy 26.4%
fatigue 23.6%
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
pyrexia 14.3% (placebo 4.5%)
myalgia 4.8% (placebo 0%)
upper respiratory tract infection 4.8% (placebo 0%)
NCT02440464 · Phase 2 · registry result, not featured evidence
4 mg + 25 mg + 40 mg
constipation 50%
upper respiratory tract infection 47.1%
diarrhoea 41.2%
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
4 mg
thrombocytopenia 100%
anaemia 66.7%
aspartate aminotransferase increased 66.7%
NCT02168101 · Phase 2 · registry result, not featured evidence
3 mg
gastritis 66.7%
thrombocytopenia 66.7%
abdominal pain 33.3%
NCT02168101 · Phase 2 · registry result, not featured evidence
2.3 mg
diarrhoea 100%
dry eye 66.7%
hypertension 66.7%
NCT02168101 · Phase 2 · registry result, not featured evidence
anaemia 30.6%
diarrhoea 30.6%
upper respiratory tract infection 25%
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 33.3%
upper respiratory tract infection 26.9%
anaemia 24.4%
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
neutropenia 47.1%
anaemia 32.4%
nausea 29.4%
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
hyperglycemia 85%
hypoalbuminemia 80%
fatigue 75%
NCT02499081 · Phase 2 · registry result, not featured evidence
4 mg
anemia 76%
platelet count decreased 76%
neutrophil count decreased 68%
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
3 mg
anemia 85.7%
lymphocyte count decreased 85.7%
white blood cell decreased 85.7%
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bThe assessment timepoint is not available for both results.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dTrial phases differ: Phase 2 versus Phase 3.
  5. eTreatment context has not been resolved for both arms.
  6. fPopulation context differs: registered conditions differ.
  7. gAssessment timepoints differ: 91 weeks versus 165 weeks.
  8. hPopulation comparability has not been reviewed for 30 of these studies.
  9. iPopulation comparability has not been reviewed for 36 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bortezomib

Complete 6.2% (n=145)
responder rate · % of participants
No placebo or comparator arm
NCT00722566 · Phase 3 · converted to % from 9 Participants as posted
show 4 more results
8.2% (n=73)*
NCT00722566 · Phase 3 · converted to % from 6 Participants as posted
3% (n=147)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
4% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
4% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
CR/sCR 42.6% (n=350) vs 24.4% (n=356) Velcade, Melphalan and Prednisone
responder rate · % of participants
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
Stringent Complete 18% (n=350) vs 7% (n=356) Velcade, Melphalan and Prednisone
responder rate · % of participants
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 5 more results
23.5% (n=98) vs 20.8% (n=96) Thalidomide + Prednisolone @ 13wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
28.6% (n=98) vs 27.1% (n=96) Thalidomide + Prednisolone @ 26wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
30.6% (n=98) vs 26% (n=96) Thalidomide + Prednisolone @ 39wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
28.6% (n=98) vs 26% (n=96) Thalidomide + Prednisolone @ 52wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
42.4% (n=99) vs 32% (n=97) Lenalidomide+Bortezomib+Dexamethasone
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Emotional Functioning 8.5 vs 9.4 Velcade, Melphalan and Prednisone score @ 13wk
absolute change · score
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 9 more results
10.8 vs 10.5 Velcade, Melphalan and Prednisone score @ 26wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
11.1 vs 11.8 Velcade, Melphalan and Prednisone score @ 39wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.6 vs 11.2 Velcade, Melphalan and Prednisone score @ 52wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.5 vs 12.8 Velcade, Melphalan and Prednisone score @ 78wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
10.7 vs 11.8 Velcade, Melphalan and Prednisone score @ 104wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.4 vs 10.8 Velcade, Melphalan and Prednisone score @ 130wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.3 vs 10.8 Velcade, Melphalan and Prednisone score @ 156wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.8 vs 6.5 Velcade, Melphalan and Prednisone score @ 182wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
10.5 vs 6.2 Velcade, Melphalan and Prednisone score @ 208wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
EQ-5D-5L VAS 9.37 vs 4.27 Velcade, Melphalan and Prednisone score @ 13wk
absolute change · score
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 9 more results
11.02 vs 7.51 Velcade, Melphalan and Prednisone score @ 26wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.51 vs 10.08 Velcade, Melphalan and Prednisone score @ 39wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
10.93 vs 11.1 Velcade, Melphalan and Prednisone score @ 52wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
15.35 vs 10.75 Velcade, Melphalan and Prednisone score @ 78wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.17 vs 10.62 Velcade, Melphalan and Prednisone score @ 104wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
14.41 vs 12.38 Velcade, Melphalan and Prednisone score @ 130wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
13.94 vs 12 Velcade, Melphalan and Prednisone score @ 156wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
14.33 vs 12.88 Velcade, Melphalan and Prednisone score @ 182wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
11.93 vs 9.17 Velcade, Melphalan and Prednisone score @ 208wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
EQ-5D-5L Index 0.12 vs 0.09 Velcade, Melphalan and Prednisone score @ 13wk
absolute change · score
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 9 more results
0.14 vs 0.12 Velcade, Melphalan and Prednisone score @ 26wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.16 vs 0.16 Velcade, Melphalan and Prednisone score @ 39wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.17 vs 0.15 Velcade, Melphalan and Prednisone score @ 52wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.17 vs 0.14 Velcade, Melphalan and Prednisone score @ 78wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.18 vs 0.15 Velcade, Melphalan and Prednisone score @ 104wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.19 vs 0.16 Velcade, Melphalan and Prednisone score @ 130wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.21 vs 0.16 Velcade, Melphalan and Prednisone score @ 156wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.2 vs 0.08 Velcade, Melphalan and Prednisone score @ 182wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.15 vs 0.07 Velcade, Melphalan and Prednisone score @ 208wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
Stringent Complete 3.2% (n=281) vs 0.7% (n=278) BTZ+LD-DEX
responder rate · % of participants
Stringent complete response
NCT01734928 · Phase 3 · registry result, not featured evidence · combination · converted to % from 9 Participants as posted
Stable Disease 11.4% (n=281) vs 38.1% (n=278) BTZ+LD-DEX
event count · % of participants
Stable Disease
NCT01734928 · Phase 3 · registry result, not featured evidence · combination · converted to % from 32 Participants as posted
Progressive Disease 3.9% (n=281) vs 5.8% (n=278) BTZ+LD-DEX
event count · % of participants
Progressive Disease
NCT01734928 · Phase 3 · registry result, not featured evidence · combination · converted to % from 11 Participants as posted
CD34 6e6 Mobilization up to 2 Apheresis 64.7% (n=17) vs 66.7% (n=21) CYCLOPHOSPHAMIDE & G-CSF @ 156wk
event count · % of participants
NCT01146834 · Phase 3 · registry result, not featured evidence · converted to % from 11 Participants as posted
show 1 more result
0% (n=4) vs 66.7% (n=21) CYCLOPHOSPHAMIDE & G-CSF @ 156wk*
NCT01146834 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
Neutrophil Recovery 100% (n=7) vs 100% (n=11) CYCLOPHOSPHAMIDE & G-CSF @ 2.86wk
event count · % of participants
NCT01146834 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted
show 1 more result
100% (n=4) vs 100% (n=11) CYCLOPHOSPHAMIDE & G-CSF @ 2.86wk*
NCT01146834 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
Neutrophil Recovery 0 vs 100% CYCLOPHOSPHAMIDE & G-CSF @ 2.86wk
event count · count
NCT01146834 · Phase 3 · registry result, not featured evidence · combination

+ 30 further endpoints in the CSV export.

Ixazomib

Pain 50.5% (n=190) vs 51.3% (n=195) placebo
responder rate · % of participants
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
Skeletal-related 10% (n=163) vs 14% (n=160) placebo
event rate · % of participants
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
25% (n=191) vs 14% (n=160) placebo
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
VGPR 40% (n=395) vs 45% (n=261) placebo
responder rate · % of participants
VGPR
NCT02181413 · Phase 3
show 1 more result
34% (n=425) vs 37% (n=281) placebo
VGPR
NCT02312258 · Phase 3
MRD Negative 17.3% (n=225) vs 19.4% (n=139) placebo
event count · % of participants
NCT02181413 · Phase 3 · converted to % from 39 Participants as posted
Sustained MRD Negative 94.9% (n=39) vs 92.6% (n=27) placebo
event count · % of participants
NCT02181413 · Phase 3 · converted to % from 37 Participants as posted
ECOG 0 vs 0.1 placebo score
absolute change · score
NCT02181413 · Phase 3
ECOG 0 vs 0 placebo score @ 4wk
absolute change · score
Cycle 2 Day 1
NCT02312258 · Phase 3
ECOG 0 vs 0 placebo score @ 8wk
absolute change · score
Cycle 3 Day 1
NCT02312258 · Phase 3
ECOG -0.1 vs 0 placebo score @ 12wk
absolute change · score
Cycle 4 Day 1
NCT02312258 · Phase 3
ECOG 0 vs 0 placebo score @ 16wk
absolute change · score
Cycle 5 Day 1
NCT02312258 · Phase 3
ECOG 0 vs 0 placebo score @ 20wk
absolute change · score
Cycle 6 Day 1
NCT02312258 · Phase 3
ECOG 0 vs 0 placebo score @ 24wk
absolute change · score
Cycle 7 Day 1
NCT02312258 · Phase 3

+ 126 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bortezomib's landscape · Ixazomib's landscape